Overcoming Barriers to Biosimilar Adoption: Commentary on "Cost to Medicare of Delayed Adalimumab Biosimilar Availability"

Clin Pharmacol Ther. 2022 Jul;112(1):25-27. doi: 10.1002/cpt.2403. Epub 2021 Sep 6.

Authors

Nitzan Arad¹, Adam Kroetsch¹, Mark McClellan¹

Affiliation

¹ Duke-Margolis Center for Health Policy, Duke University, Durham, North Carolina, USA.

PMID: 34487350
DOI: 10.1002/cpt.2403

No abstract available

Publication types

Comment

MeSH terms

Adalimumab
Aged
Biosimilar Pharmaceuticals*
Humans
Medicare
United States

Substances

Biosimilar Pharmaceuticals
Adalimumab